NRX Pharmaceuticals, Inc. NRXP 深 沪
等待开盘 05-12 09:30:00 美东时间
2.82
-0.260
-8.44%
华盛通- 最 高3.125
- 今 开3.07
- 成交量 134.00万股
- 最 低 2.80
- 昨 收 3.08
- 总市值 18.79万
- 52周最高 3.84
- 市盈率 静 --
- 换手率 2010.81%
- 52周最低 1.62
- 委 比 -49.52%
- 总股本 6.66万
- 历史最高 76.99
- 量 比 1.44
- 振 幅 10.55%
- 历史最低 0.13
- 每 手 1
- 风险率 0.50%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多NRX Pharmaceuticals Q4 EPS $0.20 Up From $(0.77) YoY, Sales $983.000K
NRX Pharmaceuticals (NASDAQ:NRXP) reported quarterly earnings of $0.20 per share. This is a 125.97 percent increase over losses of $(0.77) per share from the same period last year. The company reported $983.000 thousand
03-24 06:08
BTIG Reiterates Buy on NRX Pharmaceuticals, Maintains $25 Price Target
BTIG analyst Thomas Shrader reiterates NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains $25 price target.
01-15 17:47
Ascendiant Capital Maintains Buy on NRX Pharmaceuticals, Raises Price Target to $48
Ascendiant Capital analyst Edward Woo maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and raises the price target from $47 to $48.
01-02 17:50
Earnings Scheduled For November 17, 2025
Companies Reporting Before The Bell • So-Young Intl (NASDAQ:SY) is projected to...
2025-11-17 19:11
Earnings Outlook For NRX Pharmaceuticals
NRX Pharmaceuticals (NASDAQ:NRXP) is gearing up to announce its quarterly earni...
2025-11-14 23:02
Nurix Therapeutics to Participate in the Jefferies Global Healthcare Conference
Nurix Therapeutics executives will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 4, 2025, to discuss their targeted protein degradation medicines for cancer and inflammatory diseases.
2025-05-28 11:00
Ascendiant Capital Maintains Buy on NRX Pharmaceuticals, Raises Price Target to $44
Ascendiant Capital analyst Edward Woo maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and raises the price target from $43 to $44.
2024-09-13 01:58
HOPE Therapeutics Secures Financing For Ketamine Clinic Expansion
HOPE Therapeutics, Inc., a subsidiary of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), announced plans to acquire a network of interventional psychiatry clinics, focusing on ketamine treatments. The acquisition and financing agreements, valued at $30 million, are backed by a qualified lender. The company...
2024-08-27 06:48
NRX Pharmaceuticals Secures Non-Binding Debt Financing Agreements for Ketamine Clinics
09:02 AM EDT, 08/26/2024 (MT Newswires) -- NRX Pharmaceuticals' (NRXP) HOPE Therapeutics subsidiary said Monday it has signed a non-binding agreement for $30 million in debt financing for its first interventional psychiatric clinics using the drug ketamine. The company also signed a non-binding agre...
2024-08-26 21:02
